Synjardy XR is a once-daily prescription tablet that combines empagliflozin, an SGLT2 inhibitor, with extended-release metformin. It is FDA-approved to improve glycemic control in adults with type 2 diabetes when diet and exercise alone are not enough.
How Synjardy XR Works
Synjardy XR brings together two established diabetes medications that lower blood sugar through different mechanisms. Empagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in the kidneys, reducing how much glucose is reabsorbed into the bloodstream. Excess glucose is then excreted in the urine.
Metformin, the other component, works primarily in the liver by decreasing glucose production. It also improves how muscle and fat cells respond to insulin. The extended-release version dissolves gradually, providing steady exposure across 24 hours and often reducing the stomach upset that immediate-release metformin can cause.
By combining these two drug classes, Synjardy XR tackles elevated blood glucose from multiple angles. According to the American Diabetes Association’s Standards of Care, combination therapy is often more effective than single-drug therapy once A1C is more than 1.5 percentage points above goal.
Who Synjardy XR Is For
This medication is indicated for adults with type 2 diabetes when both components are appropriate. It is not approved for type 1 diabetes or diabetic ketoacidosis. Your doctor may consider Synjardy XR if you have tried metformin alone without reaching your A1C target, or if you have cardiovascular disease and could benefit from empagliflozin’s proven heart protection.
People exploring diabetes treatment options should understand that Synjardy XR is designed for established type 2 diabetes, not for prediabetes. If you have prediabetes, lifestyle changes and sometimes metformin alone are the typical first-line approaches.
Dosing and How to Take It
Synjardy XR is taken once a day, usually with the morning meal. Taking it with food helps reduce gastrointestinal side effects and improves absorption of the extended-release metformin matrix.
The tablet must be swallowed whole. Do not cut, crush, or chew it, because doing so disrupts the extended-release coating and can cause metformin to release too quickly. If you see what looks like an intact tablet in your stool, that is the empty shell of the extended-release matrix and is normal.
| Available Strengths | Empagliflozin | Metformin ER |
|---|---|---|
| Synjardy XR 5 mg/1000 mg | 5 mg | 1000 mg |
| Synjardy XR 10 mg/1000 mg | 10 mg | 1000 mg |
| Synjardy XR 12.5 mg/1000 mg | 12.5 mg | 1000 mg |
| Synjardy XR 25 mg/1000 mg | 25 mg | 1000 mg |
Potential Benefits Beyond Glucose Control
The empagliflozin component has been shown in large clinical trials to provide benefits that go beyond lowering blood sugar. The landmark EMPA-REG OUTCOME trial, published in the New England Journal of Medicine, found that empagliflozin reduced the risk of cardiovascular death by 38 percent in people with type 2 diabetes and established cardiovascular disease.
Additional research has shown empagliflozin may help slow the progression of chronic kidney disease and reduce hospitalizations for heart failure. Metformin, meanwhile, has decades of safety data and may offer modest protection against cardiovascular events. Together, these two drugs offer a profile that addresses several common complications of type 2 diabetes.
Common Side Effects
Like any medication, Synjardy XR can cause side effects. The most common ones relate to the individual components:
- Urinary tract infections — Higher glucose in urine creates conditions where bacteria may grow more easily.
- Genital yeast infections — More common in women, but men can experience them too.
- Increased urination — Especially in the first few weeks, as the kidneys excrete more glucose.
- Gastrointestinal upset — Nausea, diarrhea, and abdominal discomfort from metformin, usually fading over time.
- Low blood sugar — Uncommon with Synjardy XR alone but can occur when combined with insulin or sulfonylureas.
Serious Risks and Warnings
Synjardy XR carries several important warnings. The metformin component includes a boxed warning about lactic acidosis, a rare but serious condition. Risk rises with kidney impairment, dehydration, heavy alcohol use, and certain imaging procedures that use IV contrast dye.
Empagliflozin has been linked to rare cases of diabetic ketoacidosis, even when blood sugar is not especially high. If you experience nausea, vomiting, abdominal pain, fatigue, or shortness of breath, seek medical care promptly. The FDA has also noted rare cases of Fournier’s gangrene, a serious bacterial infection of the perineum that requires emergency treatment.
Dehydration and low blood pressure can occur, particularly in older adults or people taking diuretics. Staying well-hydrated is important, especially during hot weather or illness.
Who Should Avoid Synjardy XR
Synjardy XR is not appropriate for everyone. According to the FDA prescribing information, it should not be used in people with:
- Severe kidney impairment (eGFR below 30 mL/min/1.73 m2)
- Type 1 diabetes or a history of diabetic ketoacidosis
- Acute or chronic metabolic acidosis
- Known hypersensitivity to empagliflozin or metformin
- Severe liver disease
Pregnant or breastfeeding women should discuss alternatives with their doctor, as Synjardy XR is not recommended during the second and third trimesters.
Drug Interactions to Watch For
Several medications can interact with Synjardy XR. Diuretics may increase the risk of dehydration and low blood pressure. Insulin or sulfonylureas combined with Synjardy XR raise the risk of hypoglycemia and may require dose adjustments. Certain drugs, including cimetidine and some antibiotics, can raise metformin levels.
Always share a complete list of prescription drugs, over-the-counter medications, and supplements with your healthcare provider and pharmacist. This helps catch potential interactions before they cause problems.
Cost and Coverage
Synjardy XR is a brand-name medication without a generic equivalent as of this writing. Out-of-pocket costs can be significant, though most commercial insurance plans cover it with prior authorization. The manufacturer, Boehringer Ingelheim and Eli Lilly, offers a savings card that may reduce copays for eligible patients with commercial insurance.
For people without insurance, patient assistance programs may provide the medication at low or no cost. Your pharmacist or diabetes educator can help you navigate these options.
The Bottom Line
Synjardy XR offers a convenient once-daily option that pairs two proven diabetes medications. It may help lower A1C, reduce cardiovascular risk, and support modest weight loss in adults with type 2 diabetes. Because it combines two drug classes with different side effect profiles, careful patient selection and monitoring are essential. If you are considering Synjardy XR, have an open conversation with your healthcare team about your kidney function, other medications, and treatment goals to decide whether it fits your plan.
